Literature DB >> 32882448

Bacterial outer membrane vesicles induce disseminated intravascular coagulation through the caspase-11-gasdermin D pathway.

Yue Peng1, Min Gao1, Yukun Liu2, Xianhui Qiu2, Xiaoye Cheng2, Xinyu Yang2, Fangping Chen2, Erhua Wang3.   

Abstract

BACKGROUND: Disseminated intravascular coagulation (DIC), a severe complication of sepsis, promotes multiple organ dysfunctions and lethality. Bacterial infection is the most common cause of sepsis. We previously show an important role of bacteria-released outer membrane vesicles (OMVs) in bacterial infection-induced DIC. In the light of recent advance that activation of caspase-11 and its enzymatic substrate gasdermin D (GSDMD) is able to trigger coagulation, we postulate that OMVs might induce DIC through the caspase-11-GSDMD pathway.
METHODS: Caspase-11- or GSDMD-deficient mice and their wild-type (WT) controls were injected with purified Escherichia coli-derived OMVs. Blood samples were then collected. The development of DIC was assessed in terms of the occurrence of coagulopathy, the organ injuries and the lethality. Peritoneal macrophages derived from WT, Caspase-11- or GSDMD-deficient mice were stimulated with OMVs. Then the cell surface tissue factor (TF) activity and thrombin generation were assessed.
RESULTS: Genetic deletion of Caspase-11 or GSDMD or pharmacological inhibition of caspase-11 markedly attenuated OMVs-induced coagulopathy, multiple organ injuries and mortality. Caspase-11- or GSDMD-deficient macrophages exhibited markedly reduced TF activity after OMVs stimulation.
CONCLUSION: OMVs induce DIC through the caspase-11-GSDMD pathway. These findings might open a new avenue to prevent or treat bacterial infection-induced DIC.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Caspase-11; Disseminated intravascular coagulation; GSDMD; Outer membrane vesicles

Mesh:

Substances:

Year:  2020        PMID: 32882448     DOI: 10.1016/j.thromres.2020.08.013

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  Signaling pathways and intervention therapies in sepsis.

Authors:  Yun-Yu Zhang; Bo-Tao Ning
Journal:  Signal Transduct Target Ther       Date:  2021-11-25

2.  Outer membrane vesicles as molecular biomarkers for Gram-negative sepsis: Taking advantage of nature's perfect packages.

Authors:  Lea Vacca Michel; Thomas Gaborski
Journal:  J Biol Chem       Date:  2022-09-13       Impact factor: 5.486

Review 3.  Regulation, Activation and Function of Caspase-11 during Health and Disease.

Authors:  Aidan Agnew; Ciara Nulty; Emma M Creagh
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

Review 4.  Inflammasome-Dependent Coagulation Activation in Sepsis.

Authors:  Runliu Wu; Nian Wang; Paul B Comish; Daolin Tang; Rui Kang
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 7.561

5.  Investigating Morphological Changes of T-lymphocytes after Exposure with Bacterial Determinants for Early Detection of Septic Conditions.

Authors:  Kari Lavinia Vom Werth; Theresa Wörmann; Björn Kemper; Philipp Kümpers; Stefanie Kampmeier; Alexander Mellmann
Journal:  Microorganisms       Date:  2022-02-08

6.  Pyolysin of Trueperella pyogenes Induces Pyroptosis and IL-1β Release in Murine Macrophages Through Potassium/NLRP3/Caspase-1/Gasdermin D Pathway.

Authors:  Hongmin Liang; Bing Wang; Junwei Wang; Bo Ma; Wenlong Zhang
Journal:  Front Immunol       Date:  2022-03-15       Impact factor: 7.561

7.  Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic/chemo-/immunotherapy.

Authors:  Yongjiang Li; Junyong Wu; Xiaohan Qiu; Suhe Dong; Jun He; Jihua Liu; Wenjie Xu; Si Huang; Xiongbin Hu; Da-Xiong Xiang
Journal:  Bioact Mater       Date:  2022-06-29

Review 8.  Innate immune signaling and immunothrombosis: New insights and therapeutic opportunities.

Authors:  Tristram A J Ryan; Luke A J O'Neill
Journal:  Eur J Immunol       Date:  2022-05-24       Impact factor: 6.688

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.